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Abstract
Neurodegenerative and infectious disorders related to host
genetics, aging, and environment are rapidly increasing.
Drugs, vaccines, or regenerative proteins offer “real”
possibilities for positively affecting disease outcomes but
are limited by access across the blood-brain barrier. New
developments in nanomedicine and cell based drug
delivery are becoming available. These discoveries can
lead to improved neurological disease outcomes. Such
obstacles include the toxicities inherent in the delivery
systems de novo such as immuno- and neurological
dysfunctions and perturbations of blood-brain barrier func-
tion. This debate by leading expertsin the field highlights the
promise and perils of CNS drug delivery. Click on
Supplemental HTML to watch the streaming video.
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